# A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

> **NCT02196324** · PHASE2 · COMPLETED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 128 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** serlopitant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02196324
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-09
- **Primary completion:** 2016-05-27
- **Final completion:** 2016-06-10
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196324, "A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02196324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*